As an initial test of anti-β3 activity, the ability of compounds to inhibit the adhesion of melanoma cells expressing high levels of αvβ3 and low levels of other RGD-binding integrins such as αvβ5 and α5β1 to immobilised fibronectin was evaluated. The gene discussed is IGKV4-1; the disease is melanoma.